Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKesson
Fish and Richardson
Mallinckrodt
Johnson and Johnson
Express Scripts
Healthtrust
Harvard Business School
McKinsey
US Army
US Department of Justice

Generated: October 21, 2017

DrugPatentWatch Database Preview

Details for Patent: ► Subscribe

« Back to Dashboard

Details for Patent: ► Subscribe

Title:Process for preparing a semi-solid delivery vehicle comprising granisetron
Abstract: A semi-solid delivery vehicle contains a polyorthoester and an excipient, and a semi-solid pharmaceutical composition contains an active agent and the delivery vehicle. The pharmaceutical composition may be a topical, syringable, or injectable formulation; and is suitable for local delivery of the active agent. Methods of treatment are also disclosed.
Inventor(s): Ng; Steven Y. (San Francsico, CA), Shen; Hui Rong (Fremont, CA), Heller; Jorge (Ashland, OR)
Assignee: A.P. Pharma, Inc. (Redwood City, CA)
Filing Date:Oct 24, 2011
Application Number:13/279,949
Claims:1. A process for the preparation of a pharmaceutical composition comprising: (A) a semi-solid delivery vehicle, comprising: (i) a polyorthoester consisting of formula I ##STR00023## where: R* is ethyl; n is an integer of 5 to 1000; and A is R.sup.1 or R.sup.3 where R.sup.1 is: ##STR00024## where: p is an integer of 1 to 20; R.sup.5 is hydrogen; and R.sup.6 is: ##STR00025## where: s is an integer of 0 to 10; R.sup.3 is: ##STR00026## where: x is an integer of 0 to 30; in which about 0.05-30 mol percent of the A units are of the formula R.sup.1; and (ii) polyethylene glycol monomethyl ether; and (B) granisetron in an amount of 1-5 weight % of the composition; the process comprising mixing the components (A)(i) and (A)(ii) and (B) to form the composition.

2. The process of claim 1, wherein the process comprises: (1) warming the polyorthoester; (2) dissolving the granisetron in the polyethylene glycol monomethyl ether to form a solution; and (3) mixing the polyorthoester and the solution to obtain a homogeneous mixture.

3. The process of claim 1, wherein the polyethylene glycol monomethyl ether has a molecular weight between 200 and 4000.

4. The process of claim 3, wherein the polyethylene glycol monomethyl ether comprises polyethylene glycol monomethyl ether 550.

5. The process of claim 4, wherein the total concentration of the polyethylene glycol monomethyl ether is 5-60 weight % of the composition.

6. The process of claim 1, wherein the polyorthoester is a reaction product of 3,9-di(ethylidene)-2,4,8,10-tetraoxaspiro[5.5 ] undecane (DETOSU), triethylene glycol (TEG) and triethylene glycol diglycolide (TEG-diGL).

7. The process of claim 1, wherein the composition comprises 78.4 weight % polyorthoester, 19.6 weight % polyethylene glycol monomethyl ether and 2 weight % granisetron.

8. The process of claim 1, wherein p is an integer of 1 to 7 in a portion of the units of formula I.

9. The process of claim 1, wherein x is 2 in a portion of the units of formula I.

10. The process of claim 1, wherein s is 2 in a portion of the units of formula I.

11. The process of claim 1, wherein the total concentration of the polyethylene glycol monomethyl ether is 5% to 80% weight percent of the composition.

12. The process of claim 1, wherein the mixing is performed at a temperature between about 5.degree. C. and 200.degree. C.

13. The process of claim 1, wherein: the polyorthoester is a reaction product of 3,9-di(ethylidene)-2,4,8,10-tetraoxaspiro[5.5]undecane (DETOSU), triethylene glycol (TEG) and triethylene glycol diglycolide (TEG-diGL); and the polyethylene glycol monomethyl ether has a molecular weight between 200 and 4000.

14. The process of claim 1, wherein about 0.1-25 mol percent of the A units are of the formula R.sup.1.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Fish and Richardson
Johnson and Johnson
Argus Health
Chubb
US Army
Moodys
McKesson
Healthtrust
Citi
Federal Trade Commission

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot